Six products of Yuanda Pharmaceutical (00512) were successfully included in the 2026 National Medical Insurance Drug Catalogue, Commercial Insurance Innovative Drug Catalogue and Industry Supporting List

Zhitongcaijing · 2d ago

Zhitong Finance App News, Yuanda Pharmaceutical (00512) announced that recently, the Group successfully included six products in the “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue (2026)” and “Commercial Health Insurance Innovative Drug Catalogue (2026)” published by the National Medical Security Administration (National Health Insurance Administration) of the People's Republic of China, the “Commercial Health Insurance Drug Insurance Recommendation List (First Edition)” published by the China Insurance Industry Association, or “Commercial Health Insurance Insurance Cost Estimation Involving Drugs” published by the China Association of Actuaries.

The six products include: E-Gantai® (yttrium [90Y] microsphere injection) was successfully selected for the first time in the commercial insurance innovative drug catalogue and recommended list; Liteling® (olotadine mometasone nasal spray) was included in the national medical insurance drug catalogue for the first time; Enzurun® Bishelle® (indagamo inhalation powder II), Enmingrun® Bishelle® (indatromomethasone inhalation powder II, III), and Limeitong® (epleridone tablets) successfully renewed the contract and continued to remain in the national medical insurance catalogue; Anvide® (carglutamic acid dispersible tablets) was included in the commercial insurance cost schedule for the first time.

The Group believes that the collaboration between health insurance and commercial insurance is an important step for the country to “protect the basics, promote innovation” and strongly support the high-quality development of innovative drugs. The Group's six products are connected to the multi-level medical insurance system through multiple access routes, which not only helps improve the accessibility of medication for patients in related diseases and effectively reduces the burden of treatment, but also further accelerates the market penetration and coverage of products, forms a virtuous cycle from the payment side to the clinical side, and lays a solid foundation for long-term high-quality growth.